Relmada Therapeutics Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update
Positive 12-month Phase 2 data for NDV-01 in non-muscle invasive bladder cancer (NMIBC) demonstrated...
Publisher
Global
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalIn-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Summary excerpt
Positive 12-month Phase 2 data for NDV-01 in non-muscle invasive bladder cancer (NMIBC) demonstrated...
Source route
Continue on relmada.com
Leave the platform to read the original full article on the publisher site.
Source: Relmada Therapeutics
Scope: Industry
Related coverage
More related coverage
ORYZON strengthens vafidemstat patent portfolio with U.S. Notice of Allowance
BIO-Europe Spring 2026
Zymeworks Announces Participation in Upcoming Investor Conferences
News and Events
Newron presents 2025 financial results and provides 2026 outlook Ad hoc announcement pursuant to Art...